Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis
Background. The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and the risk of lung cancer in these patients is high. The use of inhaled corticosteroids (ICSs) in COPD patients could help to decrease potential lung cancer risk. We planned to conduct this systematic...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Pulmonary Medicine |
| Online Access: | http://dx.doi.org/10.1155/2022/9799858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561962493411328 |
|---|---|
| author | Amare Abera Tareke Wondwosen Debebe Addis Alem Nebiyou Simegnew Bayileyegn Taddese Alemu Zerfu Andualem Mossie Ayana |
| author_facet | Amare Abera Tareke Wondwosen Debebe Addis Alem Nebiyou Simegnew Bayileyegn Taddese Alemu Zerfu Andualem Mossie Ayana |
| author_sort | Amare Abera Tareke |
| collection | DOAJ |
| description | Background. The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and the risk of lung cancer in these patients is high. The use of inhaled corticosteroids (ICSs) in COPD patients could help to decrease potential lung cancer risk. We planned to conduct this systematic review and meta-analysis to determine the role of ICS in the risk of lung cancer among COPD patients. Methods. A comprehensive search of PubMed, Science Direct, Google Scholar, and Cochrane library and a manual search of the list of references were conducted. Studies with cohort, case-control, and randomized clinical trial designs for any ICS use reporting the incidence/hazard ratio (HR) of lung cancer were included. The random-effects model was used to pool hazard ratios. Subgroup analysis and metaregression analysis were employed. Funnel plot and Egger regression test were used to assess publication bias. Results. Combining the results of 14 observations, the pooled HR for cancer risk reduction was 0.69 (95% CI 0.59-0.79), p value ≤ 0.001. The use of ICS in COPD patients showed a 31% reduction in the risk of lung cancer. Subgroup meta-analysis showed a significant reduction in the risk of lung cancer as well. Conclusion. The use of ICS in COPD patients reduces the risk of lung cancer. The risk reduction was independent of smoking status and latency period. Future studies should focus on the optimum dose and controlling confounders like asthma. |
| format | Article |
| id | doaj-art-20511e7c66f940a9bd0b25f27c70585e |
| institution | Kabale University |
| issn | 2090-1844 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Medicine |
| spelling | doaj-art-20511e7c66f940a9bd0b25f27c70585e2025-02-03T01:23:38ZengWileyPulmonary Medicine2090-18442022-01-01202210.1155/2022/9799858Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-AnalysisAmare Abera Tareke0Wondwosen Debebe1Addis Alem2Nebiyou Simegnew Bayileyegn3Taddese Alemu Zerfu4Andualem Mossie Ayana5Department of Biomedical SciencesDepartment of Biomedical SciencesDepartment of Biomedical SciencesDepartment of SurgeryCollege of Medicine and Health SciencesDepartment of Biomedical SciencesBackground. The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and the risk of lung cancer in these patients is high. The use of inhaled corticosteroids (ICSs) in COPD patients could help to decrease potential lung cancer risk. We planned to conduct this systematic review and meta-analysis to determine the role of ICS in the risk of lung cancer among COPD patients. Methods. A comprehensive search of PubMed, Science Direct, Google Scholar, and Cochrane library and a manual search of the list of references were conducted. Studies with cohort, case-control, and randomized clinical trial designs for any ICS use reporting the incidence/hazard ratio (HR) of lung cancer were included. The random-effects model was used to pool hazard ratios. Subgroup analysis and metaregression analysis were employed. Funnel plot and Egger regression test were used to assess publication bias. Results. Combining the results of 14 observations, the pooled HR for cancer risk reduction was 0.69 (95% CI 0.59-0.79), p value ≤ 0.001. The use of ICS in COPD patients showed a 31% reduction in the risk of lung cancer. Subgroup meta-analysis showed a significant reduction in the risk of lung cancer as well. Conclusion. The use of ICS in COPD patients reduces the risk of lung cancer. The risk reduction was independent of smoking status and latency period. Future studies should focus on the optimum dose and controlling confounders like asthma.http://dx.doi.org/10.1155/2022/9799858 |
| spellingShingle | Amare Abera Tareke Wondwosen Debebe Addis Alem Nebiyou Simegnew Bayileyegn Taddese Alemu Zerfu Andualem Mossie Ayana Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis Pulmonary Medicine |
| title | Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis |
| title_full | Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis |
| title_fullStr | Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis |
| title_short | Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis |
| title_sort | inhaled corticosteroids and the risk of lung cancer in chronic obstructive pulmonary disease patients a systematic review and meta analysis |
| url | http://dx.doi.org/10.1155/2022/9799858 |
| work_keys_str_mv | AT amareaberatareke inhaledcorticosteroidsandtheriskoflungcancerinchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT wondwosendebebe inhaledcorticosteroidsandtheriskoflungcancerinchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT addisalem inhaledcorticosteroidsandtheriskoflungcancerinchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT nebiyousimegnewbayileyegn inhaledcorticosteroidsandtheriskoflungcancerinchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT taddesealemuzerfu inhaledcorticosteroidsandtheriskoflungcancerinchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis AT andualemmossieayana inhaledcorticosteroidsandtheriskoflungcancerinchronicobstructivepulmonarydiseasepatientsasystematicreviewandmetaanalysis |